Sunbelt Securities Inc. Sells 187 Shares of Zoetis Inc. (NYSE:ZTS)

Sunbelt Securities Inc. lessened its holdings in shares of Zoetis Inc. (NYSE:ZTS – Get Rating) by 3.6% in the third quarter, Holdings Channel.com reports. The firm owned 4,954 shares of the company’s stock after selling 187 shares during the period. Sunbelt Securities Inc.’s holdings in Zoetis were worth $735,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Trexquant Investment LP boosted its position in shares of Zoetis by 264.9% in the third quarter. Trexquant Investment LP now owns 32,166 shares of the company’s stock valued at $4,770,000 after acquiring an additional 23,352 shares during the period. Stock Yards Bank & Trust Co. bought a new position in shares of Zoetis in the second quarter valued at approximately $994,000. Pinnacle Associates Ltd. boosted its position in shares of Zoetis by 11.1% in the third quarter. Pinnacle Associates Ltd. now owns 7,050 shares of the company’s stock valued at $1,045,000 after acquiring an additional 702 shares during the period. U.S. Capital Wealth Advisors LLC boosted its position in shares of Zoetis by 77.8% in the third quarter. U.S. Capital Wealth Advisors LLC now owns 9,951 shares of the company’s stock valued at $1,476,000 after acquiring an additional 4,354 shares during the period. Finally, Personal Capital Advisors Corp boosted its position in shares of Zoetis by 5.5% in the third quarter. Personal Capital Advisors Corp now owns 1,950 shares of the company’s stock valued at $289,000 after acquiring an additional 102 shares during the period. Institutional investors own 90.23% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. Barclays lifted their target price on shares of Zoetis from $250.00 to $260.00 and gave the company an “overweight” rating in a research report on Tuesday, February 21st. StockNews.com assumed coverage on shares of Zoetis in a research report on Thursday. They set a “buy” rating for the company. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $223.83.

Zoetis Trading Down 1.1 %

ZTS stock opened at $164.47 on Friday. The company has a market capitalization of $76.21 billion, a PE ratio of 36.55, a price-to-earnings-growth ratio of 2.55 and a beta of 0.76. Zoetis Inc. has a one year low of $124.15 and a one year high of $201.32. The company’s 50 day moving average price is $165.25 and its two-hundred day moving average price is $155.26. The company has a debt-to-equity ratio of 1.49, a quick ratio of 1.63 and a current ratio of 2.37.

Zoetis (NYSE:ZTS – Get Rating) last posted its quarterly earnings results on Tuesday, February 14th. The company reported $1.15 EPS for the quarter, hitting the consensus estimate of $1.15. The firm had revenue of $2.04 billion for the quarter, compared to the consensus estimate of $2.01 billion. Zoetis had a net margin of 26.16% and a return on equity of 50.20%. The business’s revenue was up 3.7% compared to the same quarter last year. During the same period last year, the firm posted $1.00 earnings per share. As a group, analysts predict that Zoetis Inc. will post 5.39 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 1st. Shareholders of record on Friday, April 21st will be paid a dividend of $0.375 per share. This represents a $1.50 annualized dividend and a dividend yield of 0.91%. The ex-dividend date of this dividend is Thursday, April 20th. Zoetis’s dividend payout ratio (DPR) is presently 33.33%.

Zoetis Profile

(Get Rating)

Zoetis, Inc engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. The firm operates through the United States and International geographical segments. The United States segment is involved in U.S.